CeriBell (CBLL) Stock Price, News & Analysis

Company Overview

CeriBell (NASDAQ:CBLL) is a medical technology company specializing in non-invasive point-of-care ultrasound solutions for obstetric and gynecologic applications. Founded in 2016 and headquartered in Wayne, Pennsylvania, the company leverages proprietary imaging hardware and cloud-based analytics to support clinicians in prenatal monitoring, women’s health diagnostics, and maternal-fetal care. CeriBell’s systems are designed to deliver rapid, real-time insights at the bedside, reducing reliance on centralized imaging facilities and streamlining patient workflows.

The company’s flagship offering, the CeriScan Point-of-Care Ultrasound System, integrates advanced transducer technology with software algorithms for automated image capture and analysis. Key functional capabilities include biometric measurements, fetal heart rate assessment, and uterine activity monitoring. By combining compact, handheld devices with secure data transmission, CeriBell enables remote interpretation and telehealth collaboration, helping providers make informed decisions during routine prenatal visits, labor management and high-risk screenings.

CeriBell markets its products primarily in North America, with ongoing expansion efforts in Europe and Latin America. The firm partners with hospitals, outpatient clinics and telemedicine networks to broaden adoption of point-of-care ultrasound in both urban and underserved regions. In addition to clinical deployments, CeriBell collaborates with academic institutions on research initiatives aimed at enhancing maternal and neonatal outcomes through early detection of complications such as fetal distress, placental insufficiency and preterm labor.

Led by Chief Executive Officer Rohit Bhalla, CeriBell’s management team combines expertise in medical imaging, regulatory affairs and global commercialization. The Board of Directors includes seasoned executives from the healthcare and technology sectors, guiding the company’s strategy to innovate diagnostic tools that advance women’s health. As CeriBell continues to develop new applications and expand its footprint, it remains focused on improving access to quality prenatal care and elevating clinical decision-making at the point of care.

Key Stats

• Today's Range: $16.12 to $16.80
• 50-Day Range: $15.85 to $19.65
• 52-Week Range: $10.01 to $32.75
• Volume: 131,165 shs
• Average Volume: 290,379 shs
• Market Capitalization: $582.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.14
• Consensus Rating: Buy

CeriBell Stock Analysis - MarketRank™

CeriBell scored higher than 53% of companies evaluated by MarketBeat, and ranked 508th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CeriBell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CeriBell has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CeriBell are expected to grow in the coming year, from ($2.46) to ($1.18) per share.

Price to Book Value per Share Ratio

CeriBell has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBLL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CeriBell does not currently pay a dividend.

Dividend Growth

CeriBell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CBLL.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.34

News Sentiment

CeriBell has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for CeriBell this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added CeriBell to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,337,695.00 in company stock.

Percentage Held by Insiders

20.10% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.

CBLL Stock Analysis - Frequently Asked Questions

How have CBLL shares performed this year?

CeriBell's stock was trading at $25.88 on January 1st, 2025. Since then, CBLL stock has decreased by 37.7% and is now trading at $16.13.

How were CeriBell's earnings last quarter?

CeriBell, Inc. (NASDAQ:CBLL) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business earned $20.49 million during the quarter, compared to the consensus estimate of $19.30 million.
Read the conference call transcript.

When did CeriBell IPO?

CeriBell (CBLL) raised $180 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 10,606,060 shares at $17.00 per share.

How do I buy shares of CeriBell?

Shares of CBLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CBLL
• Previous Symbol: NASDAQ:CBLL
• CIK: 1861107
• Web: N/A
• Phone: (800) 436-0826
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CeriBell: $32.14
• High Price Target: $36.00
• Low Price Target: $30.00
• Potential Upside/Downside: +99.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 17.36
• Quick Ratio: 16.81

Sales & Book Value

• Annual Sales: $65.44 million
• Price / Sales: 8.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.34 per share
• Price / Book: 3.02

Miscellaneous

• Outstanding Shares: 36,140,000
• Free Float: 28,878,000
• Market Cap: $582.94 million
• Optionable: N/A
• Beta: N/A